Impact of rheumatoid arthritis in the public health system in Santa Catarina, Brazil: a descriptive and temporal trend analysis from 1996 to 2009

Gomes, Rafael Kmiliauskis Santos; Pires, Fabio Antero; Nobre, Moacyr Roberto Cucê; Marchi, Mauricio Felippi de Sá; Rickli, Jennifer Cristina Kozechen

doi:10.1016/j.rbre.2016.07.003

Cited by 4 publications

(3 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The first restriction refers to the number of RA patients treated by the SUS with biologic medicines. These studies [48,50,56] record data from 1996 facilitated by the MoHB (only 10% of RA patients used biological medicines). The second concerns access in the medicines availability dimension: the restriction rate adopted was 50%, based on published studies and other sources between 1998 and 2005 [57][58][59][60].…”

Section: Values Determined With the Modeled Calculation Of The Budget...mentioning

confidence: 99%

Budget impact analysis of medicines: estimated values versus real-world evidence and the implications

Faleiros

Álvares-Teodoro

Silva

et al. 2021

Expert Review of Pharmacoeconomics & Outcomes Research

View full text Add to dashboard Cite

Objectives: Budget Impact Analyses (BIA) of medicines helps managers in promoting health systems' sustainability when assessing the role and value of new medicines. However, it is not clear whether BIAs typically underestimate or overestimate the impact on real-world budgets. This retroactive analysis seeks to compare estimated values obtained by a BIA and Real-World Evidence (RWE) to guide discussions. Methods: The estimated values were obtained through a BIA concerning the incorporation of adalimumab for the treatment of Rheumatoid Arthritis into the Brazilian Unified Health System (SUS) carried out retroactively and per international guidelines. RWE data was extracted from SUS computerized systems. We subsequently compared the number of treatments, costs, and Incremental Budget Impact (IBI). Results -The total number of treatments was underestimated by 10% (6,243) and the total expenditure was overestimated by 463% (US$ 4.7 billion). In five years, the total difference between the estimated values and real IBI reached US$ 1.1 billion. A current expenditure of US$ 1.0 was observed for every US$ 5.60 of estimated expenditure. Conclusion -The higher estimates from the BIA might cause decision makers to be more cautious in the introduction of the new drug to reduce the opportunity costs for other interventions.

show abstract

Section: Values Determined With the Modeled Calculation Of The Budget...mentioning

confidence: 99%

Budget impact analysis of medicines: estimated values versus real-world evidence and the implications

Faleiros

Álvares-Teodoro

Silva

et al. 2021

Expert Review of Pharmacoeconomics & Outcomes Research

View full text Add to dashboard Cite

show abstract

“…Brazilian Journal of Development, Curitiba, v.7, n.9, p. 91805-91819 sep. 2021 Dentre estas doenças a artrite reumatoide tem merecido mais atenção pelas consequências que podem causar ao paciente senão tratada corretamente (GOMES, 2017).…”

Section: Introductionunclassified

Revisão sistemática sobre os efeitos fitoterápicos da uncaria tomentosa e uncaria guianensis na artrite reumatoide e osteoartrite / Systematic review on the herbal effects of uncaria tomentosa and uncaria guianensis in rheumatoid arthritis and osteoarthritis

Zeferino¹,

Laurentino²,

Barros³

et al. 2021

BJDV

View full text Add to dashboard Cite

Introdução: A artrite reumatoide (AR) é uma doença crônica, progressiva, autoimune e de causa desconhecida. É caracterizada por inflamação persistente que afeta principalmente as articulações periféricas. Por ser uma doença sem cura, muitos medicamentos, incluindo os fitoterápicos são utilizados na intenção de se ter um controle da doença. Nesse contexto, a Uncaria tomentosa e a Uncaria guianensis são opções utilizadas como tratamento alternativo por populares, uma vez que o fitoterápico atua em processos inflamatórios articulares, pela suas propriedades antioxidantes, antivirais, antiinflamatórias e antirreumáticas.

show abstract

“…Total annual cost per patient in 2008 was R$19 860 (Brazilian real; slightly less than US$10 000), which included medi-38 The costs per month for RA patients were 6.6 times higher than for non-RA beneficiaries. A time-series study with cross-sectional survey of data from the Hospital and Outpatient Information System from 1996 to 2009 showed that the total RA expenses for hospital and outpatient medical treatment in Santa Catarina were R$26 659 127.20 39. proach based on the society perspective, the estimated indirect cost was US$2427.64 per patient per year.…”

mentioning

confidence: 99%

The burden of illness of rheumatoid arthritis in Latin America—A systematic literature review

Papadimitropoulos

Brnabic²,

Vorstenbosch

et al. 2022

Int J of Rheum Dis

View full text Add to dashboard Cite

Rheumatoid arthritis (RA) is an autoimmune disease characterized by inflammation and progressive destruction of joints. 1 Over 23 million people worldwide suffer from RA. The disease has variable expression and outcome ranging from mild, limited disease to severe disease associated with progressive joint destruction and reduced survival. 1 Substantial comorbidity can be seen outside the musculoskeletal system, with excess cardiovascular risk, dyslipidemia, and propensity for infection partially related to the need for treatment with immunomodulatory agents. 2 Furthermore, RA causes a significant reduction in quality of life (QoL), impacting the physical, emotional, occupational, and economic aspects of patients' lives. 3 The combination of costs associated with long-term therapy and socio-economic consequences of RA have a major impact on healthcare systems and on society in general. 4

show abstract

Impact of rheumatoid arthritis in the public health system in Santa Catarina, Brazil: a descriptive and temporal trend analysis from 1996 to 2009

Abstract: During the observed period, a reduction in the number of hospital admissions for both clinical and orthopedic surgical procedures related to this disease was observed. Nevertheless, there was an increase in the cost of medical admissions.

Cited by 4 publications

References 18 publications

Budget impact analysis of medicines: estimated values versus real-world evidence and the implications

Budget impact analysis of medicines: estimated values versus real-world evidence and the implications

Revisão sistemática sobre os efeitos fitoterápicos da uncaria tomentosa e uncaria guianensis na artrite reumatoide e osteoartrite / Systematic review on the herbal effects of uncaria tomentosa and uncaria guianensis in rheumatoid arthritis and osteoarthritis

The burden of illness of rheumatoid arthritis in Latin America—A systematic literature review

Contact Info

Product

Resources

About